Results 161 to 170 of about 2,763 (183)

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

Headache, 2021
Koichi Hirata
exaly  

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes

Therapeutics and Clinical Risk Management, 2022
Raffaele Ornello, Simona Sacco, Eleonora de Matteis   +2 more
exaly  

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial

Cephalalgia, 2022
Uwe Reuter, Axel Heinze, Shihua Wen
exaly  

Safety and tolerability evaluation of erenumab for the preventive treatment of migraine

Expert Opinion on Drug Safety, 2021
Messoud Ashina
exaly  

Efficacy of erenumab in chronic migraine patients with and without ictal allodynia

Cephalalgia, 2021
Dana Franznick, Jan Klatt, David Dodick   +2 more
exaly  

Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis

Journal of Pain and Palliative Care Pharmacotherapy, 2021
Nadia Khalil, Yuanyuan Lu
exaly  

Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment

Journal of Clinical Medicine, 2023
Angelo Torrente, Massimo Autunno, Cecilia Camarda   +2 more
exaly  

Erenumab/galcanezumab

Reactions Weekly, 2022
openaire   +1 more source

Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine

Headache, 2020
Katrina Devick, Jennifer Robblee, Amaal Starling   +2 more
exaly  

Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention

Annals of Pharmacotherapy, 2019
John G Gums
exaly